Clinical Trial

A Phase III Study of KHN939 in Chinese Patients With Moderate-to-Severe Active Thyroid Eye Disease

Study acronym: Halo-1
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a multicenter, randomized, double-masked, placebo-controlled Phase 3 study to evaluate the efficacy, safety, immunogenicity, and population pharmacokinetic (PopPK) characteristics of KHN939 in Chinese patients with moderate-to-severe active thyroid eye disease (TED). Approximately 60 participants who meet the study eligibility criteria will be randomized in a 2:1 ratio (stratified by smoking status) to receive 8 infusions of KHN939 or placebo q3W.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-07-17.
Trial Details
NCT Number NCT07720635
Lead Sponsor Beijing Kanghong Biological Medicine Co., Ltd.
Conditions Thyroid Eye Disease
Enrollment 60 participants
Start Date 2026-08
Primary Completion 2027-04 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-23